|
Company background Cyplasin Biomedical Ltd. was originally incorporated
pursuant to the laws of the State of Nevada on May 12, 2004 under the
name Glass Wave Enterprises, Inc. Effective February 16, 2007, we changed
our name to Cyplasin Biomedical Ltd. and effected a stock split of
our authorized, issued and outstanding common stock after we entered
into an asset purchase agreement dated February 1, 2007 with Professor
Christian Petzelt. The asset purchase agreement saw the company acquiring
certain intellectual property rights pertaining to cancer treatments,
specifically protein molecules, for potential applications in treating
various cancers in exchange for the issuance by our company of shares
of our common stock. On April 10, 2007, we entered into an asset purchase
agreement with Bioxen Ltd. to acquire other related intellectual property.
The closing of the transactions in this asset purchase agreement and
the acquisition of the intellectual property occurred on April 10,
2007. The company believes the Cyplasin protein in
general might be useful as a therapeutic drug
against multiple types of cancer and the first developed application
will be Cyplasin-SC™ for
the treatment of skin cancer and human melanoma. The Company has initiated pilot preclinical
trials for Cyplasin-SC to demonstrate the efficacy/toxicity profile
in animals. These studies along with several others will generate the
data required for submission to the various regulatory authorities
to initiate the next step in product development, which are clinical
trials in humans. The finished product may be delivered to the
patient either by intravenous injection into the bloodstream or by
injection under the skin close to the tumor via a topical microinjection
to the tumour mass. Current studies suggest Cyplasin can either cause
the death of the whole tumor, or if used in tandem with current surgical
procedures will kill any remaining cancer cells which might metastasize
or spread to other parts of the body via the blood circulation system,
after the tumor has been removed by conventional surgery. Cyplasin Biomedical Ltd., headquartered in Edmonton, Alberta, Canada. Most of the current preclinical program is outsourced to competent third party Clinical Research Organizations (CRO) located in Europe and North America. |
|
Cyplasin is a public company registered on the OTC bulletin board under the trading symbol CYPL, and the Frankfurt Exchange under the trading symbol XYIA. |